Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- 1 April 2017
- journal article
- practice guideline
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (4) , 338-358
Abstract
No abstract availableKeywords
This publication has 400 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature reviewClinical Rheumatology, 2012
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility LociThe American Journal of Human Genetics, 2012
- Nonmelanoma skin cancer in inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feedingInflammatory Bowel Diseases, 2010
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2010
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- A controlled trial of azathioprine in Crohn's diseaseDigestive Diseases and Sciences, 1975